Morgan Stanley
RNTX

Morgan Stanley’s Rein Therapeutics RNTX Stock Holding History

Morgan Stanley’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,300
Closed -$7.61K – 8329
2025
Q1 		$7.61K Hold
4,300
– – ﹤0.01% 6883
2024
Q4 		$9.89K Sell
4,300
-1,250
-23% -$3.79K ﹤0.01% 6804
2024
Q3 		$19.6K Buy
5,550
+4,300
+344% +$11.5K ﹤0.01% 6507
2024
Q2 		$3.46K Hold
1,250
– – ﹤0.01% 6947
2024
Q1 		$8.29K Sell
1,250
-1,250
-50% -$5.98K ﹤0.01% 6764
2023
Q4 		$7.62K Buy
2,500
+1,250
+100% +$2.44K ﹤0.01% 6896
2023
Q3 		$1.9K Hold
1,250
– – ﹤0.01% 7144
2023
Q2 		$2.24K Hold
1,250
– – ﹤0.01% 7174
2023
Q1 		$1.55K Hold
1,250
– – ﹤0.01% 7285
2022
Q4 		$2.96K Sell
1,250
-1
-0.1% -$3 ﹤0.01% 7270
2022
Q3 		$5K Buy
1,251
+1
+0.1% +$4 ﹤0.01% 7262
2022
Q2 		$7K Sell
1,250
-221
-15% -$2.03K ﹤0.01% 7334
2022
Q1 		$15K Sell
1,471
-33,415
-96% -$302K ﹤0.01% 7269
2021
Q4 		$393K Buy
34,886
+32,463
+1,340% +$502K ﹤0.01% 5692
2021
Q3 		$50K Buy
2,423
+537
+28% +$11.8K ﹤0.01% 6728
2021
Q2 		$47K Buy
1,886
+1,301
+222% +$32.5K ﹤0.01% 6699
2021
Q1 		$17K Buy
+585
New +$20K ﹤0.01% 6784
2019
Q3 		– Sell
-1,475
Closed -$21K – 6784
2019
Q2 		$21K Sell
1,475
-18,432
-93% -$483K ﹤0.01% 5921
2019
Q1 		$776K Buy
19,907
+561
+3% +$17.5K ﹤0.01% 4278
2018
Q4 		$325K Sell
19,346
-2,050
-10% -$82.4K ﹤0.01% 5057
2018
Q3 		$1.18M Buy
21,396
+20,344
+1,934% +$1.37M ﹤0.01% 4410
2018
Q2 		$114K Buy
1,052
+167
+19% +$18.9K ﹤0.01% 5708
2018
Q1 		$144K Buy
885
+478
+117% +$85.2K ﹤0.01% 5600
2017
Q4 		$86K Buy
407
+85
+26% +$20.4K ﹤0.01% 5679
2017
Q3 		$86K Buy
+322
New +$80.8K ﹤0.01% 5617

Other funds holding RNTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

Morgan Stanley's RNTX Position: Q2 2025 in Review

Morgan Stanley sold out of Rein Therapeutics (RNTX) in Q2 2025, closing a stake of 4,300 shares — an estimated $7.61K sold.

Morgan Stanley first reported a position in RNTX in Q3 2017 and held it in 25 quarters. The position peaked at $1.18M in Q3 2018. 36 funds tracked by Wall St. Rank hold RNTX as of Q2 2025.

  • Morgan Stanley reported no remaining Rein Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Morgan Stanley sold 4,300 Rein Therapeutics shares in Q2 2025, an estimated $7.61K.
  • Morgan Stanley first reported a position in Rein Therapeutics in Q3 2017 and held it in 25 quarters.
  • Morgan Stanley's Rein Therapeutics position peaked at $1.18M in Q3 2018.
  • 36 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.